Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity

  • Cuyàs, Elisabet|||0000-0001-5353-440X
  • Pedarra, Stefano
  • Verdura, Sara|||0000-0001-8980-0423
  • Pardo-Cea, Miguel Ángel|||0000-0003-4823-6613
  • Espin Garcia, Roderic|||0000-0003-2494-0964
  • Serrano-Hervás, Eila|||0000-0002-9477-0350
  • Llop-Hernández, Àngela
  • Teixidor, Eduard
  • Bosch-Barrera, J.|||0000-0002-0893-7821
  • López-Bonet, Eugeni
  • Martin-Castillo, Begoña
  • Lupu, Ruth|||0000-0002-5564-3172
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Sardanyés, Josep|||0000-0001-7225-5158
  • Alarcón Cor, Tomás|||0000-0002-8566-3676
  • Menéndez, Javier A.|||0000-0001-8733-4561
Fatty acid synthase (FASN)-catalyzed endogenous lipogenesis is a hallmark of cancer metabolism. However, whether FASN is an intrinsic mechanism of tumor cell defense against T cell immunity remains unexplored. To test this hypothesis, here we combined bioinformatic analysis of the FASN-related immune cell landscape, real-time assessment of cell-based immunotherapy efficacy in CRISPR/Cas9-based FASN gene knockout (FASN KO) cell models, and mathematical and mechanistic evaluation of FASN-driven immunoresistance. FASN expression negatively correlates with infiltrating immune cells associated with cancer suppression, cytolytic activity signatures, and HLA-I expression. Cancer cells engineered to carry a loss-of-function mutation in FASN exhibit an enhanced cytolytic response and an accelerated extinction kinetics upon interaction with cytokine-activated T cells. Depletion of FASN results in reduced carrying capacity, accompanied by the suppression of mitochondrial OXPHOS and strong downregulation of electron transport chain complexes. Targeted FASN depletion primes cancer cells for mitochondrial apoptosis as it synergizes with BCL-2/BCL-X-targeting BH3 mimetics to render cancer cells more susceptible to T-cell-mediated killing. FASN depletion prevents adaptive induction of PD-L1 in response to interferon-gamma and reduces constitutive overexpression of PD-L1 by abolishing PD-L1 post-translational palmitoylation. FASN is a novel tumor cell-intrinsic metabolic checkpoint that restricts T cell immunity and may be exploited to improve the efficacy of T cell-based immunotherapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mitochondrial priming and response to BH3 mimetics in "one-two punch" senogenic-senolytic strategies

  • López, Júlia
  • Llop-Hernández, Àngela
  • Verdura, Sara|||0000-0001-8980-0423
  • Serrano-Hervás, Eila|||0000-0002-9477-0350
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
  • Bosch-Barrera, J.|||0000-0002-0893-7821
  • Teixidor, Eduard
  • López-Bonet, Eugeni
  • Martin-Castillo, Begoña
  • Sardanyés, Josep|||0000-0001-7225-5158
  • Alarcón Cor, Tomás|||0000-0002-8566-3676
  • Lupu, Ruth|||0000-0002-5564-3172
  • Cuyàs, Elisabet|||0000-0001-5353-440X
  • Menéndez, Javier A.|||0000-0001-8733-4561
A one-two punch sequential regimen of senescence-inducing agents followed by senolytic drugs has emerged as a novel therapeutic strategy in cancer. Unfortunately, cancer cells undergoing therapy-induced senescence (TIS) vary widely in their sensitivity to senotherapeutics, and companion diagnostics to predict the response of TIS cancer cells to a specific senolytic drug are lacking. Here, we hypothesized that the ability of the BH3 profiling assay to functionally measure the mitochondrial priming state-the proximity to the apoptotic threshold-and the dependencies on pro-survival BCL-2 family proteins can be exploited to inform the sensitivity of TIS cancer cells to BH3-mimetics. Replicative, mitotic, oxidative, and genotoxic forms of TIS were induced in p16 -null/ p53 -proficient, BAX -deficient, and BRCA1 -mutant cancer cells using mechanistically distinct TIS-inducing cancer therapeutics, including palbociclib, alisertib, doxorubicin, bleomycin, and olaparib. When the overall state of mitochondrial priming and competence was determined using activator peptides, the expected increase in overall mitochondrial priming was an exception rather than a generalizable feature across TIS phenotypes. A higher level of overall priming paralleled a higher sensitivity of competent TIS cancer cells to BCL-2/BCL-xL- and BCL-xL-targeted inhibitors when comparing TIS phenotypes among themselves. Unexpectedly, however, TIS cancer cells remained equally or even less overally primed than their proliferative counterparts. When sensitizing peptides were used to map dependencies on anti-apoptotic BCL-2 family proteins, competent TIS cancer cells appeared to share a dependency on BCL-xL. Furthermore, regardless of senescence-inducing therapeutic, stable/transient senescence acquisition, or genetic context, all TIS phenotypes shared a variable but significant senolytic response to the BCL-xL-selective BH3 mimetic A1331852. These findings may help to rethink the traditional assumption of the primed apoptotic landscape of TIS cancer cells. BCL-xL is a conserved anti-apoptotic effector of the TIS BCL2/BH3 interactome that can be exploited to maximize the efficacy of "one-two punch" senogenic-senolytic strategies.